5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
Decision brief
Answer first · skim in under a minute
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
Notable Oncology FDA Approvals Granted in May 2026 spanned bladder, breast, cholangiocarcinoma, AML-supportive oral regimens, and mantle cell lymphoma. This B2B brief ties each decision to FDA notification pages and trial IDs so BD and competitive-intelligence teams can update pipeline maps without recycling unsourced claims.
Contents10 sections
Key Takeaways
- May 28, 2026: durvalumab + BCG approved for BCG-naïve high-risk NMIBC (POTOMAC, NCT03528694; DFS HR 0.68).
- May 1, 2026: vepdegestrant (Veppanu) approved for ESR1-mutated ER+/HER2− advanced breast cancer after endocrine therapy.
- May 8, 2026: zenocutuzumab-zbco (Bizengri) approved for NRG1-fusion advanced cholangiocarcinoma after prior systemic therapy.
- May 13–15, 2026: sonrotoclax accelerated approval in R/R MCL; Enhertu gained two HER2+ early breast indications; oral decitabine/cedazuridine + venetoclax approved in unfit AML.
Which Notable Oncology FDA Approvals Granted reshaped NMIBC?
On May 28, 2026, FDA approved durvalumab in combination with Bacillus Calmette-Guérin for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
Efficacy came from Phase III POTOMAC (NCT03528694), which randomized 1,018 patients after TURBT. Investigator-assessed disease-free survival improved versus BCG induction/maintenance alone (HR 0.68; 95% CI 0.50–0.93; P=0.0154). Recommended durvalumab dose for patients ≥30 kg is 1,500 mg every 4 weeks for up to 13 cycles with BCG, per the FDA approval notice.
What breast and rare-tumor decisions landed earlier in May?
On May 1, 2026, FDA approved vepdegestrant (Veppanu) for estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, listed among 2026 novel drug approvals.
On May 8, 2026, FDA approved zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy—an ultra-rare molecular niche flagged on the same oncology notifications board.
How did hematologic approvals on May 13 change options?
FDA granted accelerated approval to sonrotoclax (Beqalzi) on May 13, 2026 for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic lines including a Bruton’s tyrosine kinase inhibitor.
The same day, FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia in adults 75 or older or with comorbidities precluding intensive induction—expanding outpatient-capable regimens versus IV hypomethylating backbones.
What Enhertu early-breast labels arrived on May 15?
Per FDA’s oncology approval notifications, on May 15, 2026 FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate HER2-positive early-stage breast cancer indications: a neoadjuvant T-DXd followed by THP pathway in Stage II/III disease, and an adjuvant residual-invasive-disease setting after neoadjuvant trastuzumab (± pertuzumab) and taxane-based treatment.
- Biomarker gate: HER2-positive by IHC 3+ or ISH+ on an FDA-authorized test
- Competitive pressure: intensifies adjuvant/neoadjuvant HER2 sequencing debates versus legacy THP-only paths
- Companion watch: molecular residual disease strategies elsewhere in May bladder oncology
What should BD teams prioritize after this May wave?
Update competitive matrices for BCG-naïve NMIBC immunotherapy combinations, ESR1-mutated breast degraders/PROTACs, NRG1-fusion solid tumors, and oral venetoclax partnerships. Trial enrollment for head-to-head or sequencing studies will tighten where new standards reset DFS or response benchmarks.
Use the FDA oncology/hematologic malignancies approval notifications page as the canonical chronology rather than secondary roundups.
What remains unproven after these labels?
Accelerated approvals (for example sonrotoclax) still depend on confirmatory evidence. Real-world adoption of durvalumab + BCG will hinge on BCG supply, infusion capacity, and DFS durability beyond the trial median follow-up window. Do not attribute the NMIBC decision to NIAGARA; that program is a separate bladder-cancer dataset—POTOMAC is the registrational trial named in FDA’s NMIBC notice.
Related NovaPharma coverage
- Gilead Hepcludex FDA approval for hepatitis D
- Eli Lilly gene therapy cholesterol deals
- Weekly Buzz: PHG, KMDA, FULC, RMD, NVS catalysts
Frequently Asked Questions
Which Notable Oncology FDA Approvals Granted in May include NMIBC?
On May 28, 2026, FDA approved durvalumab (Imfinzi) in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on the Phase III POTOMAC trial (NCT03528694), which showed a disease-free survival hazard ratio of 0.68 versus BCG alone.
What other Notable Oncology FDA Approvals Granted hit in early May 2026?
FDA approved vepdegestrant (Veppanu) on May 1 for ESR1-mutated ER-positive, HER2-negative advanced breast cancer after endocrine therapy; zenocutuzumab-zbco (Bizengri) on May 8 for NRG1-fusion cholangiocarcinoma; and accelerated approval of sonrotoclax (Beqalzi) on May 13 for relapsed/refractory mantle cell lymphoma after at least two prior lines including a BTK inhibitor.
Did Enhertu receive early breast cancer labels in May 2026?
Yes. On May 15, 2026, FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate HER2-positive early-stage breast cancer indications spanning neoadjuvant and adjuvant residual-disease settings, per FDA oncology approval notifications.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for durvalumab.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…